
1. vaccines (basel). 2015 mar 18;3(1):186-202. doi: 10.3390/vaccines3010186.

comparison current regulatory status gene-based vaccines u.s.,
europe japan.

nakayama y(1), aruga a(2).

author information: 
(1)cooperative major advanced biomedical sciences, joint graduate school of
tokyo women's medical university waseda university, 8-1, kawada-cho,
shinjuku-ku, tokyo 162-8666, japan. yoshi-nakayama@fuji.waseda.jp.
(2)cooperative major advanced biomedical sciences, joint graduate school of
tokyo women's medical university waseda university, 8-1, kawada-cho,
shinjuku-ku, tokyo 162-8666, japan. aruga.atsushi@twmu.ac.jp.

gene-based vaccines typified plasmid dna vaccines recombinant
viral-vectored vaccines expected promising solutions infectious
diseases effective prophylactic vaccines exist hiv, dengue
virus, ebola virus malaria, improved vaccines needed
such tuberculosis influenza virus. although many preclinical clinical 
trials conducted date, dna vaccines recombinant viral-vectored
vaccines expressing heterologous antigens human use yet licensed in
the u.s., europe japan. research, describe current regulatory
context gene-based prophylactic vaccines infectious disease the
u.s., europe, japan. identify important considerations, particular,
on preclinical assessments would allow vaccines proceed to
clinical trials, differences regulatory pathway marketing 
authorization region.

doi: 10.3390/vaccines3010186 
pmcid: pmc4494244
pmid: 26344953 

